Chronic Kidney Disease (CKD) is one of the most significant yet underrecognized public health crises facing California today. Defined as lasting damage to the kidneys that can worsen over time, CKD affects millions of Californians across all demographics — but its burden falls hardest on communities of color, lower-income populations, people with co-occurring conditions such as diabetes and hypertension, and those without consistent access to healthcare.
In California, an estimated 4.4 million adults are living with CKD — and a staggering 3.96 million of them are entirely unaware of their diagnosis. This near-total lack of awareness makes CKD a true “silent killer”: it progresses without obvious symptoms until it reaches advanced stages, often culminating in kidney failure (end-stage renal disease, or ESRD) that requires dialysis or a transplant to survive.
The state’s burden of kidney disease is worsened by systemic inequities: racial and ethnic minorities face dramatically higher rates of kidney failure; rural agricultural communities in the Central Valley experience some of the highest ESRD rates in the nation; and dialysis patients face a fragmented, underfunded care system that struggles to meet growing demand. Meanwhile, research funding for kidney disease lags far behind other chronic conditions, leaving innovation in nephrology stagnant.
This article consolidates available statistical data on CKD in California — covering prevalence by demographics, kidney failure, dialysis, transplants, acute kidney injury trends, disease in special populations, geographic hotspots, financial burden, and systemic gaps — to provide a comprehensive picture of this growing crisis.
Overall CKD Prevalence in California
| Statistic | Value |
|---|---|
| Adults living with CKD (estimated) | 4.4 million |
| Adults unaware of their CKD diagnosis | 3.96 million (90%) |
| Adults who reported being told they have kidney disease | 3.9% |
| California’s national rank (overall CKD prevalence) | 23rd out of 49 states |
| At-risk Californians being properly tested for CKD | ~22% |
California’s overall CKD rate of 3.9% mirrors national trends, but the massive gap between actual disease burden (4.4 million) and diagnosed cases (~440,000 aware) reveals a profound diagnostic failure. With only 22% of at-risk individuals being properly tested, the state’s prevention and early detection infrastructure is critically inadequate.
CKD Prevalence by Demographics
By Sex
- Female: 4.2% — ranked 22nd out of 49 states
- Male: 3.6% — ranked 23rd out of 49 states
Women in California have a slightly higher reported CKD prevalence than men (4.2% vs. 3.6%). However, in populations with co-occurring conditions like sickle cell disease, males experience significantly higher CKD rates — suggesting the overall female prevalence may reflect greater engagement with healthcare and diagnosis.
By Age Group
| Age Group | California Value | National Rank |
|---|---|---|
| Ages 18-44 | 1.5% | 29th / 44 |
| Ages 45-64 | 5.2% | 44th / 49 |
| Ages 65+ | 7.3% | 9th / 49 |
CKD prevalence rises sharply with age, from 1.5% in younger adults to 7.3% in those 65 and over. California ranks particularly poorly for the 45-64 age group (44th nationally), suggesting that middle-aged Californians may face above-average risk factors or insufficient diagnosis and treatment in this critical window for intervention.
By Race/Ethnicity
- Black: 5.2% — ranked 16th out of 29 states
- Asian: 4.4% — not ranked nationally
- White: 3.6% — ranked 14th out of 49 states
- Hispanic: 3.4% — ranked 9th out of 24 states
Black Californians carry the highest reported CKD burden at 5.2%, consistent with national disparities. However, when considering kidney failure (ESRD), the racial gap is even more stark: Black Americans nationwide are 3.4 times more likely to develop kidney failure than White Americans. Hispanic Californians show a relatively lower CKD prevalence, but disproportionate ESRD rates in agricultural communities suggest access and detection gaps.
By Education Level
| Education Level | California Value | National Rank |
|---|---|---|
| Less than High School | 6.8% | 24th / 35 |
| High School Grad / GED | 2.4% | 1st / 49 (lowest rate nationally) |
| Some Post-High School | 5.1% | 26th / 49 |
| College Graduate | 3.7% | 32nd / 49 |
The highest CKD prevalence is among those with less than a high school education (6.8%), nearly three times the rate of high school graduates (2.4%). California’s high school graduate group ranks 1st nationally — meaning it has the lowest CKD rate among that group compared to other states. This likely reflects the intersection of socioeconomic factors, healthcare access, and lifestyle conditions tied to educational attainment.
By Income Level
- Less than $25,000/year: 5.5% — ranked 3rd out of 48 states (near highest nationally)
- $25,000-$49,999/year: 5.6% — ranked 25th out of 49 states
- $75,000-$99,999/year: 4.0% — ranked 25th out of 43 states
- $150,000 or more/year: 2.1% — ranked 16th out of 31 states
A clear income gradient exists: CKD prevalence is more than twice as high among the lowest-income Californians compared to the highest earners (5.5% vs. 2.1%). Alarmingly, California ranks 3rd highest nationally for CKD in adults earning under $25,000, indicating that low-income Californians face a disproportionate and above-average national burden of kidney disease.
By Disability Status
| Disability Category | California Value | National Rank |
|---|---|---|
| Difficulty Seeing | 12.8% | 34th / 44 |
| Difficulty Hearing | 11.3% | 36th / 47 |
| Difficulty with Mobility | 11.1% | 15th / 49 |
| Difficulty with Self-Care | 9.2% | 5th / 47 |
| Independent Living Difficulty | 8.0% | 7th / 49 |
| Difficulty with Cognition | 5.0% | 10th / 49 |
| Without a Disability | 2.3% | 21st / 49 |
Californians with disabilities experience CKD at rates 3-6 times higher than those without disabilities. Particularly alarming is the 12.8% rate among adults with difficulty seeing, and California’s near-top national rankings for self-care difficulty (5th) and independent living difficulty (7th), suggesting that the most vulnerable disabled populations in California face compounding health burdens relative to the rest of the nation.
Kidney Failure (End-Stage Renal Disease) in California
Current Kidney Failure Burden
- Total Californians living with kidney failure: 110,332
- Californians currently on dialysis: 81,297
- Californians living with a kidney transplant: 29,035
- New kidney failure cases diagnosed in 2019: 16,780
- Of new 2019 cases: began dialysis: 16,488
- Of new 2019 cases: received kidney transplant: 292
- Increase in kidney failure cases since 2009: +45.7%
Kidney failure in California is at crisis scale and growing. The nearly 46% rise in total cases since 2009 reflects an aging population, increasing rates of diabetes and hypertension, and patients living longer on dialysis. The ratio of new patients beginning dialysis vs. receiving a transplant — 16,488 vs. 292 in 2019 — underscores how severely the transplant system is outpaced by demand.
Leading Causes of Kidney Failure
- Diabetes: 47% of all kidney failure cases
- High Blood Pressure (Hypertension): 28% of all kidney failure cases
Together, diabetes and high blood pressure account for 75% of all kidney failure cases in California. As diabetes rates stabilized in the early 2010s, so too did the most rapid growth in acute kidney injury hospitalizations — a direct link confirmed by spatiotemporal county-level analysis showing an increasingly strong correlation between diabetes prevalence and AKI rates over time.
Racial/Ethnic Disparities in Kidney Failure
| Group (compared to White Americans) | Relative Likelihood of Developing Kidney Failure |
|---|---|
| Black Americans | 3.4x greater |
| American Indian / Alaska Native | 1.9x greater |
| Hispanic / Latino | 1.5x greater |
| Asian Americans | 1.3x greater |
The racial disparity in kidney failure is among the most severe in all of American medicine. Black Americans are 3.4 times more likely than White Americans to develop kidney failure — a gap that reflects longstanding inequities in healthcare access, exposure to risk factors, and the legacy of structural racism in healthcare systems. These patterns are mirrored in AKI hospitalization data, where Black Californians are hospitalized at 2.1 times the rate of all Californians.
Dialysis in California
Growth in Dialysis Patients and Clinics Over Time
| Year | Dialysis Patients | Dialysis Clinics |
|---|---|---|
| 2009 | 95,317 | 420 |
| 2010 | 104,761 | 450 |
| 2011 | 102,984 | 466 |
| 2012 | 109,819 | 477 |
| 2013 | 118,056 | 501 |
| 2014 | 125,567 | 524 |
| 2015 | 132,542 | 536 |
| 2016 | 139,348 | 543 |
California’s dialysis patient population increased by approximately 46% in just eight years (2009-2016), even as the number of new cases leveled off. This growth is driven by patients surviving longer on dialysis due to improved management of co-occurring cardiovascular disease and infections. The number of dialysis clinics grew from 420 to 543 — a 29% increase — but still lagged behind patient volume growth, reflecting increasing pressure on facilities.
Dialysis Industry Control
- Two for-profit corporations control nearly three-quarters of California dialysis clinics:
- DaVita Kidney Care (Denver-based)
- Fresenius Medical Care (Germany-based)
- Both companies have expanded by acquiring smaller dialysis providers as national demand has grown.
The concentration of dialysis care in two large for-profit corporations raises questions about care quality, geographic equity, and financial incentives. Both companies have expanded by acquiring smaller providers, potentially reducing competition and community-oriented care.
Economic and Social Impact of Dialysis
- More than 80% of people on dialysis cannot work — dialysis is classified as a disability.
- Each day, 360 patients nationally begin dialysis.
- Roughly 40% of those who require dialysis ‘crash’ into it — they were unaware of their kidney disease until an acute episode required immediate dialysis.
- Treating kidney failure and its comorbidities is more consuming than a full-time job.
The economic and life-quality toll of dialysis is immense. The fact that 40% of patients are unaware they have kidney disease before requiring emergency dialysis points directly to the failure of early detection systems. Early diagnosis and intervention could prevent or delay kidney failure for millions, reducing both human suffering and economic costs.
Kidney Transplants in California
| Statistic | Value |
|---|---|
| Californians on kidney transplant waiting list | 18,211 |
| Transplants performed in California (2021) | 2,777 |
| Increase in transplants from 2011 to 2021 | +33.8% |
| Living donor transplants (2021) | 609 |
| Deceased donor transplants (2021) | 2,168 |
| Change in living donor transplants since 2011 | +1.2% |
| Ratio: wait-listed patients who received transplant (2021) | Approximately 1 in 7 |
With 18,211 Californians on the transplant waiting list and only 2,777 transplants performed in 2021, only about 1 in 7 waiting patients received a transplant that year. While overall transplant volume grew 33.8% since 2011, living donor transplants barely increased (1.2%), indicating that growth is almost entirely dependent on deceased donors — a more limited and variable supply.
Financial Burden and Assistance
American Kidney Fund Assistance in California (2021)
- AKF charitable assistance to California patients (2021): $13,016,113
- California patients receiving AKF grants (2021): 3,588
- AKF assistance ratio — White Americans with kidney failure: 1 in 17
- AKF assistance ratio — Black Americans with kidney failure: 1 in 10
- AKF assistance ratio — Hispanic/Latino Americans with kidney failure: 1 in 10
Insurance Breakdown of AKF Assistance Recipients (National)
| Insurance Type | % of Recipients |
|---|---|
| Medicare Part B | 36.8% |
| Medigap | 31.1% |
| Employer group health plans (including COBRA) | 18.9% |
| Commercial plans | 10.5% |
| Exchange | 3.4% |
| Annuity | 1.5% |
| Medicare Advantage | 1.2% |
| Medicaid (in states that charge premiums) | 0.1% |
The disproportionate reliance of Black and Hispanic patients on charitable assistance (1 in 10 vs. 1 in 17 for White patients) reflects the compounding burden of higher kidney failure rates, lower incomes, and more limited insurance coverage among minority communities. Over $13 million in charitable assistance was required just to keep California’s most vulnerable dialysis and transplant patients insured in a single year.
Research Funding Disparity
NIH spending per patient by disease (2023):
- HIV/AIDS: $2,745 per patient
- Alzheimer’s Disease: $528 per patient
- Cancer: $423 per patient
- Kidney Disease: $19 per patient
The contrast is stark: kidney disease receives just $19 per patient in NIH research funding, compared to $2,745 for HIV/AIDS — a 144-fold difference. Given that kidney disease is the 8th leading cause of death in the United States and affects more than 35 million people nationally, this level of research investment is profoundly disproportionate to the disease burden. This underfunding directly constrains innovation in nephrology.
Acute Kidney Injury (AKI) Trends in California (2005-2015)
Overall AKI Episode Growth
- Total AKI episodes in 2005 (hospital + ED): 25,495
- Total AKI episodes in 2015 (hospital + ED): 48,845
- Overall change 2005-2015: +91.6% (nearly doubled)
- Hospital (inpatient) admissions 2005 to 2015: 24,845 to 42,996 (+173%)
- Emergency Department visits 2005 to 2015: 650 to 5,849 (+900%)
- Hospitalizations for all conditions (same period): Decreased from 3,990,255 to 3,833,043
- ED visits for all conditions (same period): Increased +144.5%
AKI episodes in California nearly doubled in just a decade, but the most alarming trend is the 900% increase in emergency department visits — suggesting more patients are arriving in acute crisis rather than being managed preventively. The dramatic increase in ED visits relative to hospitalizations indicates delayed care-seeking and inadequate outpatient management of at-risk patients.
AKI Episodes by Comorbidities
| Comorbidity Status | % of AKI Episodes |
|---|---|
| Diabetes or hypertension (combined) | 83.3% |
| Both diabetes and hypertension | 39.4% |
| Hypertension only (no diabetes) | 37.7% |
| Diabetes only (no hypertension) | 6.1% |
| CKD as a co-existing condition | ~51.2% |
| AKI hospitalizations with diabetes/hypertension, increase 2005 to 2015 | 19,880 to 36,674 (+92%) |
| AKI hospitalizations without diabetes/hypertension, increase 2005 to 2015 | 4,965 to 6,322 (+27%) |
Nine of ten AKI cases were associated with diabetes or hypertension — and the share of AKI episodes with these comorbidities grew from 80% (2005) to 85% (2015) in hospitals. The increasing overlap between AKI and CKD (present in about half of all cases) reflects the bidirectional relationship: each condition dramatically increases risk for the other, creating a vicious cycle of kidney damage.
AKI Hospitalization Rate by Race/Ethnicity (per 10,000 residents)
| Race/Ethnicity | 2005-2008 | 2009-2011 | 2012-2015 | Ratio vs. All CA |
|---|---|---|---|---|
| White | 7.79 | 8.03 | 8.97 | 0.9x |
| Hispanic | 11.32 | 12.18 | 13.03 | 1.3x |
| African American | 18.90 | 19.78 | 21.78 | 2.1x |
| Asian | 6.04 | 6.05 | 6.17 | 0.6-0.7x |
| Native American | 3.91 | 4.77 | 6.04 | 0.4-0.6x |
| Unknown / Other | 16.64 | 15.43 | 20.69 | 1.7-2.0x |
| Total (all California) | 8.85 | 9.26 | 10.24 | 1.0x |
African Americans are hospitalized for AKI at 2.1 times the rate of all Californians — the highest ratio of any racial group — and this disparity remained constant across all three time periods, indicating no improvement over a decade. Hispanic patients show a persistent 1.3x elevated rate. These patterns closely mirror the disparities seen in kidney failure data, pointing to systemic and structural drivers rather than individual risk factors alone.
County-Level AKI Hotspots (2011-2013)
Counties exceeding 180 AKI hospitalizations per 100,000 population:
- Lake County: 261.5 per 100,000
- Butte County: 236.6 per 100,000
- Kings County: 211.6 per 100,000
- Stanislaus County: 207.4 per 100,000
- Yuba County: 204.2 per 100,000
- Merced County: 196.7 per 100,000
- Shasta County: 194.1 per 100,000
- Tuolumne County: 190.4 per 100,000
- San Bernardino County: 189.3 per 100,000
- Kern County: 186.0 per 100,000
- Solano County: 185.3 per 100,000
- San Joaquin County: 182.4 per 100,000
- Tehama County: 181.0 per 100,000
- Glenn County: 180.7 per 100,000
The geographic clustering of high AKI rates in Central Valley counties — Merced, Kings, Stanislaus, San Joaquin, Kern — is consistent with the region’s elevated rates of agricultural employment, high heat exposure, pesticide exposure, and limited healthcare access. These counties are largely the same regions identified in studies of unexplained end-stage renal disease.
Unexplained ESKD and Agricultural Exposure in the Central Valley
- ESKD incidence in California’s Central Valley: ~396 per million population (one of highest nationally)
- ZIP codes with high unexplained ESKD also having above-average groundwater nitrates: 85%
- Environmental nitrate data analyzed: 2010-2014
- ESKD diagnoses studied: 2015-2017
- Age range of cases studied: 18-60 years
Pilot Study Demographics (Soledad Dialysis Unit)
| Characteristic | Value |
|---|---|
| Participants interviewed | 31 of 44 eligible |
| Median age | 49 years |
| Hispanic/Latino | 94% |
| Had no health insurance or coverage interruptions before dialysis | 32% |
| Had agricultural work history | 84% |
| ESKD cause classified as unknown | 25% |
| ESKD cause: Diabetes | 52% |
| ESKD cause: Glomerulonephritis / Vasculitis | 10% |
| Education: None | 10% |
| Education: Less than 9th grade | 32% |
| Education: High School / GED | 42% |
| Education: Some college / AA degree | 16% |
This pilot study paints a striking picture: the majority of unexplained ESKD patients in one Central Valley dialysis unit were Hispanic/Latino (94%), worked in agriculture (84%), had limited education, and nearly a third lacked consistent health insurance before starting dialysis. Whether the elevated ESKD rates stem from pesticide or chemical exposure, occupational heat stress, groundwater contamination, or healthcare access gaps remains under investigation — but the convergence of these risk factors is unmistakable.
CKD in Special Populations
CKD in People Living with HIV (PLWDH) in California (2015-2020)
| Statistic | Value |
|---|---|
| PLWDH in California with diagnosed CKD | 12% |
| PLWDH aged 60+ with CKD | 26% |
| PLWDH hospitalized in prior 12 months who also had CKD | 21% |
| PLWDH with ER visit in prior 12 months who also had CKD | 15% |
| PLWDH with diagnosed diabetes who also had CKD | 26% |
| PLWDH with diagnosed hypertension who also had CKD | 21% |
| PLWDH with diagnosed Hepatitis C who also had CKD | 15% |
| Total PLWDH interviewed (California MMP, 2015-2020) | 3,275 |
CKD affects 12% of HIV-positive Californians receiving care — below the 15% national adult average, though this comparison may reflect differences in age, access to care, and surveillance methodology. The sharp increase to 26% among PLWDH aged 60+ and among those with co-occurring diabetes highlights the compounding impact of multiple chronic conditions in this population.
CKD in Californians with Sickle Cell Disease (SCD) (2011-2020)
- Adults with SCD studied: 2,345-2,992 (two study cohorts)
- CKD prevalence in SCD adults : 22.8% (681 of 2,992)
- CKD prevalence in SCD adults : 24.4% (572 of 2,345)
- Mean age of cohort at mid-point of study : 40.1 years
- Mean age at first CKD code : 48 years
- Males with CKD : 26.7%
- Females with CKD : 20.4%
CKD prevalence by age among SCD patients :
- Ages 18-29: 8%
- Ages 30-39: 17%
- Ages 40-49: 24%
- Ages 50-59: 44.6%
- Ages 60+: 51.1%
The following data on disease progression, mortality, and access to specialized care reveals the critical burden of CKD among sickle cell disease patients in California:
- Of CKD patients: latest recorded stage was ESRD: 40%
- Deaths during the 10-year study period: 478 (15.9% of total cohort)
- Of all deaths: occurred in the CKD subgroup: 50.8%
- Median age at death — CKD cohort: 53 years
- Median age at death — non-CKD cohort: 43 years
- SCD-CKD patients with zero hematologist visits per year: 48-49.1%
- SCD-CKD patients with zero nephrologist visits per year: 61-61.9%
CKD is an extraordinarily severe complication of sickle cell disease in California, affecting nearly one in four adults with SCD. By age 60, over half of SCD patients have CKD. The mortality data is alarming: over half of all deaths in the study occurred in the CKD subgroup, despite them representing only about 23% of the total cohort. Most devastating is the access-to-care data: nearly half had no hematologist visits and over 60% had no nephrologist visits during a 10-year period — for a disease requiring both specialists.
CKD Mortality in California (2022)
- Male residents (California): 85.7 deaths per 100,000
- Female residents (California): 67.1 deaths per 100,000
- Non-Hispanic American Indian / Alaska Native: 129.8 per 100,000 (highest in state)
- Non-Hispanic Black residents: 129.7 per 100,000 (second highest)
- San Diego County: 60.9 per 100,000 (lower than California and US averages)
Male Californians die from CKD at a rate 28% higher than females. The death rate among American Indian/Alaska Native and Black Californians (approximately 130 per 100,000) is more than double that of the overall state, representing one of the most extreme racial health disparities in California. San Diego County’s significantly lower rate (60.9) suggests that geography, healthcare access, and demographic differences create meaningful variation in outcomes across the state.
Systemic Gaps and Policy Challenges
Medicare Reimbursement Shortfalls
- CMS has consistently provided insufficient payment updates to dialysis providers, failing to reflect rising labor and medical supply costs.
- Many dialysis centers — including nonprofit and rural facilities — have been forced to close.
- Patients may face significantly longer travel distances to reach dialysis care, especially in rural communities.
Access to Innovative Treatments
- Medicare provides enhanced reimbursement for new ESRD treatments for only 2 years after FDA approval.
- After 2 years, reimbursement drops sharply — sometimes to pennies on the dollar.
- This discourages prescribing of innovative medications and reduces incentives for manufacturers to develop new therapies.
- In 2023, NIH spent just $19 per kidney disease patient on research, compared to $423 per cancer patient and $2,745 per HIV/AIDS patient.
Legislative Response
- The bipartisan Kidney Care Access Protection Act (S. 2730 / H.R. 6214) has been proposed.
- The bill would stabilize reimbursement by tying payment updates to real economic conditions.
- It would create a long-term pathway for new therapies beyond the current 2-year reimbursement window.
The policy environment surrounding kidney care is failing patients at multiple levels. Underfunded dialysis reimbursements threaten facility viability; 2-year caps on innovative treatment reimbursement undermine clinical adoption and pharmaceutical R&D incentives; and $19 per patient in NIH research funding leaves the field scientifically starved. Reform is needed across research funding, clinical reimbursement, and access-to-care policy simultaneously.
Conclusion
Chronic kidney disease in California represents a sprawling and deepening public health emergency. The data presented in this article reveal consistent and interconnected themes: CKD is underdiagnosed at a massive scale, falls disproportionately on communities of color and low-income populations, is driven primarily by the diabetes and hypertension epidemics, and is under-resourced in research, reimbursement, and clinical capacity.
The Central Valley’s unexplained ESKD hotspots, the devastating burden on sickle cell disease patients, the near-inaccessibility of transplants for those on waiting lists, and the 900% growth in emergency AKI visits all point to a system that is reacting to crises rather than preventing them. With only 22% of at-risk Californians being properly tested, and 3.96 million of the state’s CKD patients unaware of their diagnosis, early detection and equitable access to care must become immediate priorities.
Addressing this crisis requires action across multiple fronts: expanding CKD screening in primary care — especially in high-risk communities; increasing NIH research funding to levels commensurate with disease burden; stabilizing Medicare reimbursement for dialysis providers; reforming innovative therapy coverage; and investing in agricultural community health infrastructure where environmental and occupational exposures may be driving an epidemic of unexplained kidney disease. The data are clear. The solutions are known. What remains is the political and public will to act.
Resources:
- Explore Chronic Kidney Disease in the United States | AHR
- California Ending Disparities in CKD Leadership Summits | National Kidney Foundation
- Medical Monitoring Project (MMP) – HIV and Chronic Kidney Disease, 2015-2020
- Unexplained kidney disease in California more likely near agriculture
- Burden of Chronic Kidney Disease in Californians with Sickle Cell Disease | Blood | American Society of Hematology
- Prevalence, Mortality, and Access to Care for Chronic Kidney Disease in Medicaid-Enrolled Adults With Sickle Cell Disease in California: Retrospective Cohort Study
- Kidney failure in California: 2022
- Kidney Diseases by the Numbers
- Kidney Disease Statistics | UKRO – University Kidney Research Organization
- End-Stage Kidney Disease of Unknown Etiology: Studying a Hotspot in California’s Central Valley 18194
- The Expanding Burden of Acute Kidney Injury in California: Impact of the Epidemic of Diabetes on Kidney Injury Hospital Admissions – PMC
- CHRONIC KIDNEY DISEASE
- Congress Must Step Up for the Millions of Americans Battling Kidney Disease | The Well News
- Number Of Dialysis Patients In California Surges